Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The androgen receptor is a transcription factor activated by the testosterone metabolite 5α-dihydrotestosterone and regulates the expression of genes related to sexual differentiation, growth and survival of prostate cells, and to a certain extent, cancer progression.
|
31712062 |
2020 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These ΔLBD androgen receptor variants have shown the capability to induce androgen receptor-mediated gene transcription even under conditions of androgen deprivation and to drive cancer progression.
|
30659302 |
2020 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive tumour progression.
|
31006810 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We have previously reported that deubiquitinase USP14 stabilizes AR proteins by deubiquitination and USP14 inhibition results in inhibition of cell growth and tumor progression in AR-positive prostate cancer and breast cancer.
|
31126320 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Importantly, TGF-β signaling and microRNA-mediated regulation of gene expression often act in complicated feedback circuits that involve other crucial regulators of cancer progression (e.g., androgen receptor).
|
31842336 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CONCLUSIONS The present results suggest that targeting of PLCε/BMP-6/SMAD signaling may increase the sensitivity of CRPC to AR antagonists and inhibit tumor progression.
|
31201297 |
2019 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Whether the AR gene also transcribes non-coding circular RNAs that are associated with PCa development and tumor progression remains unclear.
|
31760376 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
While BHC80-2 does not induce neuroendocrine differentiation of cancer cells, it stimulates cell proliferation and tumor progression independent of androgen receptor signaling.
|
30910347 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these data credential CHD1 as a tumor suppressor in the prostate that constrains AR binding/function to limit tumor progression.
|
30930119 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The androgen receptor (AR) is tightly linked to prostate cancer, but the mechanisms by which AR transactivation is dysregulated during cancer progression are not fully explored.
|
31152093 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Specifically, androgen receptor activation appears to be associated with increased risks of developing ovarian cancer and inducing tumor progression.
|
30791431 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Changes in androgen receptor signaling from androgen deprivation therapy have been linked to therapeutic resistance and tumor progression.
|
29345000 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.
|
29592878 |
2018 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
This study demonstrated a possible interaction of gene (AR-Q polymorphism) and environmental toxins (e.g.BaP) to affect cancer progression.
|
28782227 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The androgen receptor (AR) is the classical target for prostate cancer prevention and treatment, but more recently estrogens and their receptors have also been implicated in prostate cancer development and tumor progression.
|
29094395 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, the biological action of AR in these cells and its effect on cancer progression remains to be fully understood.
|
29618577 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Taken together, we hypothesize that IL-1 reprograms AR positive (AR<sup>+</sup> ) PCa cells into AR negative (AR<sup>-</sup> ) PCa cells that co-opt IL-1 signaling to ensure AR-independent survival and tumor progression in the inflammatory tumor microenvironment.
|
29527701 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We filtered this module by identifying genes that functionally interacted with AR variants using a high-throughput synthetic genetic array screen in <i>Schizosaccharomyces pombe</i> This strategy identified seven AR variant-regulated genes that also enhance AR activity and drive cancer progression.
|
30108134 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, steroidal drugs with a 3β-hydroxyl, Δ<sup>5</sup>-structure, such as abiraterone, are also metabolized by 3β-HSD1, and 5α-abiraterone, a downstream metabolite, has been shown to activate the androgen receptor, potentially driving cancer progression.
|
29231195 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Notably, emerging preclinical evidence has indicated the involvement of androgen receptor (AR) signaling in urothelial cancer progression.
|
29720561 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Here we report evidence to show that AR is a key mediator of inflammatory signals in ESCC cancer progression.
|
27801498 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Co-amplification of the Golgi protein coding YIPF6 gene with the AR may enhance the secretion of pro-coagulative EVs from cancer cells and thereby stimulate tumor progression and increase the coagulopathy risk in CRPC patients.Prostate 77: 625-638, 2017.
|
28144969 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
|
28011482 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Inverse correlations detected between tumor grade and AR/androgen metabolizing enzyme also suggested that the loss of AR and androgen-producing enzymes could be associated with tumor progression.
|
28947209 |
2017 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Androgen receptor plays a pivotal role in prostate cancer progression, and androgen deprivation therapy to intercept androgen receptor signal pathway is an indispensable treatment for most advanced prostate cancer patients to delay cancer progression.
|
28475016 |
2017 |